Economic model of Ulipristal Acetate in the long term, intermittent treatment of uterine fibroids — a Canadian setting

Health economic evaluation provides a comparison on the incremental costs between two interventions and whether this extra cost is justifiable by the incremental clinical benefits. It has been increasingly used by payers to inform drug reimbursement decision as it can answer the question on whether a new health technology will provide value-for-money. Consequently, alongside clinical data, the economic evidence can have an impact on a product’s market access. Ulipristal acetate is currently approved in Canada for the pre-operative management of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. However, both its regulatory and reimbursed indications are limited to a three-month treatment period and interest exists on its potential for longer periods of treatment. However, to allow reimbursement beyond three months, additional economic data are necessary. As a result, the purpose of this internship is to better understand the potential economic attractiveness of the long-term indication by pursuing an early economic modelling exercise.

Faculty Supervisor:

Daria O'Reilly

Student:

Partner:

Actavis Specialty Pharmaceuticals Co

Discipline:

Mathematics

Sector:

Wholesale trade

University:

McMaster University

Program: